ReviewFrontiers in medicine2021
Variability in Global Prevalence of Interstitial Lung Disease.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 11 syntheses or guidelines pooled it.
- Cough burden in progressive pulmonary fibrosis: a systematic review with narrative synthesis.Health and quality of life outcomes · 2026Pooled it
- Low muscle mass in interstitial lung disease: a systematic review and meta-analysis of prevalence and clinical associations.BMC pulmonary medicine · 2026Pooled it
- Clinical characteristics and mortality risk of sarcopenia in interstitial lung disease: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Interstitial lung disease epidemiology and etiology in patients with solid malignant tumors: a systematic literature review.Future oncology (London, England) · 2025Pooled it
- Clinical care in interstitial lung disease: a critical appraisal of clinical guidance documents.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Transcriptomics of interstitial lung disease: a systematic review and meta-analysis.The European respiratory journal · 2025Pooled it
- Serum surfactant protein D as a significant biomarker for predicting occurrence, progression, acute exacerbation, and mortality in interstitial lung disease: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- A meta-analysis of the clinical significance of neutrophil-to-lymphocyte ratios in interstitial lung disease.PloS one · 2023Pooled it
- Effect of noninvasive respiratory support on interstitial lung disease with acute respiratory failure: A systematic review and meta-analysis.Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR · 2023Pooled it
- Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis.Advances in respiratory medicine · 2022Guideline
- Functional status following pulmonary rehabilitation in people with interstitial lung disease: A systematic review and meta-analysis.Chronic respiratory diseasePooled it
- Contemporary Concise Review 2025: Interstitial Lung Disease.Respirology (Carlton, Vic.) · 2026Review
- Idiopathic Pulmonary Fibrosis update, comparing the Australasian Interstitial Lung Disease Registry to the Australian Idiopathic Pulmonary Fibrosis Registry.Internal medicine journal · 2026Article
- Advances in pharmacotherapy for fibrotic interstitial lung disease.Medical review (2021) · 2026Review
- Incidence and prevalence of interstitial lung diseases in Norway: analysis of the national Norwegian patient registry.BMC pulmonary medicine · 2026Article
- Diagnostic and Prognostic Value of Serum Surfactant Protein D in Interstitial Lung Disease: A Systematic Review.Cureus · 2026Review
- Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review.The European respiratory journal · 2026Review
- Neuropsychiatric disorders in pulmonary fibrosis: from brain network alterations to inflammatory mechanisms and therapeutic implications.Journal of neuroinflammation · 2026Review
- Molecular endotypes predict differential response to immunosuppressant therapy in non-idiopathic pulmonary fibrosis interstitial lung disease.American journal of respiratory and critical care medicine · 2026Observational
- Interstitial lung disease in psoriasis: A systematic review and meta-analysis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are limited epidemiologic studies describing the global burden and geographic heterogeneity of interstitial lung disease (ILD) subtypes. We found that among seventeen methodologically heterogenous studies that examined the incidence, prevalence and relative frequencies of ILDs, the incidence of ILD ranged from 1 to 31.5 per 100,000 person-years and prevalence ranged from 6.3 to 71 per 100,000 people. In North America and Europe, idiopathic pulmonary fibrosis and sarcoidosis were the most prevalent ILDs while the relative frequency of hypersensitivity pneumonitis was higher in Asia, particularly in India (10.7-47.3%) and Pakistan (12.6%). The relative frequency of connective tissue disease ILD demonstrated the greatest geographic variability, ranging from 7.5% of cases in Belgium to 33.3% of cases in Canada and 34.8% of cases in Saudi Arabia. These differences may represent true differences based on underlying characteristics of the source populations or methodological differences in disease classification and patient recruitment (registry vs. population-based cohorts). There are three areas where we feel addition work is needed to better understand the global burden of ILD. First, a standard ontology with diagnostic confidence thresholds for comparative epidemiology studies of ILD is needed. Second, more globally representative data should be published in English language journals as current literature has largely focused on Europe and North America with little data from South America, Africa and Asia. Third, the inclusion of community-based cohorts that leverage the strength of large databases can help better estimate population burden of disease. These large, community-based longitudinal cohorts would also allow for tracking of global trends and be a valuable resource for collective study. We believe the ILD research community should organize to define a shared ontology for disease classification and commit to conducting global claims and electronic health record based epidemiologic studies in a standardized fashion. Aggregating and sharing this type of data would provide a unique opportunity for international collaboration as our understanding of ILD continues to grow and evolve. Better understanding the geographic and temporal patterns of disease prevalence and identifying clusters of ILD subtypes will facilitate improved understanding of emerging risk factors and help identify targets for future intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.